IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Get Free Report) has received a consensus recommendation of "Moderate Buy" from the fourteen research firms that are presently covering the stock, Marketbeat reports. Two equities research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the company. The average 1 year price objective among brokerages that have issued a report on the stock in the last year is $54.27.
Separately, JPMorgan Chase & Co. increased their price objective on IDEAYA Biosciences from $63.00 to $66.00 and gave the company an "overweight" rating in a research report on Thursday, May 22nd.
Check Out Our Latest Report on IDEAYA Biosciences
IDEAYA Biosciences Stock Performance
Shares of IDYA stock traded down $0.06 during mid-day trading on Monday, hitting $21.86. 1,046,553 shares of the stock traded hands, compared to its average volume of 1,029,630. IDEAYA Biosciences has a twelve month low of $13.45 and a twelve month high of $44.42. The company's 50-day simple moving average is $19.34 and its 200-day simple moving average is $21.05. The firm has a market cap of $1.91 billion, a price-to-earnings ratio of -6.09 and a beta of 0.04.
IDEAYA Biosciences (NASDAQ:IDYA - Get Free Report) last released its earnings results on Tuesday, May 6th. The company reported ($0.82) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.75) by ($0.07). During the same period in the previous year, the business earned ($0.53) earnings per share. Analysts forecast that IDEAYA Biosciences will post -3.07 earnings per share for the current year.
Institutional Trading of IDEAYA Biosciences
A number of hedge funds have recently made changes to their positions in the stock. Janus Henderson Group PLC increased its stake in IDEAYA Biosciences by 13.5% in the 4th quarter. Janus Henderson Group PLC now owns 5,857,639 shares of the company's stock valued at $150,606,000 after buying an additional 695,263 shares during the period. Norges Bank purchased a new position in shares of IDEAYA Biosciences during the 4th quarter valued at $13,385,000. Millennium Management LLC increased its stake in shares of IDEAYA Biosciences by 345.2% in the first quarter. Millennium Management LLC now owns 547,637 shares of the company's stock worth $8,970,000 after acquiring an additional 424,625 shares during the last quarter. MPM Bioimpact LLC acquired a new position in shares of IDEAYA Biosciences in the fourth quarter worth $10,641,000. Finally, FMR LLC raised its holdings in shares of IDEAYA Biosciences by 2.6% during the fourth quarter. FMR LLC now owns 12,963,151 shares of the company's stock worth $333,153,000 after acquiring an additional 327,498 shares in the last quarter. 98.29% of the stock is owned by hedge funds and other institutional investors.
About IDEAYA Biosciences
(
Get Free ReportIDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.
Featured Articles

Before you consider IDEAYA Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and IDEAYA Biosciences wasn't on the list.
While IDEAYA Biosciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.